Prevymis FDA Approval History
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.
Development Timeline for Prevymis
|Nov 9, 2017||FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.